(Note: A similarly named but unrelated Vitals RX did receive an FDA warning letter in September 2025, but it is not the same pharmacy.) Additionally, Belle received an FDA warning letter in February of 2026 and was cited for misbranding after putting Belle labels on compounded GLP-1s
Supply alerts notify patients which pharmacy is reported to have supply, including the specific GLP-1 medication and dose, pharmacys name, address, and phone number
This category of drugs is likely to continue to gain FDA approval for additional indications
Even if semaglutide and tirzepatide do not meaningfully enter breast milk, GLP-1 therapy during breastfeeding carries indirect risks that deserve serious attention
One of the newest investigational drugs generating attention is retatrutide
The optical density at 570nm or fluorescence intensity at ex/em = 530/585 nm is directly proportional to the L-Carnitine concentration in the sample